ストックスクリーナーアプリを入手
145.47
0.99%
-1.41
前日終値:
$146.88
開ける：
$144.81
24時間の取引高:
1.05M
Relative Volume:
0.50
時価総額：
$276.45B
収益：
$54.66B
当期純損益:
$13.58B
株価収益率:
20.73
EPS:
7.0171
ネットキャッシュフロー:
$16.05B
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
-5.45%
6か月 パフォーマンス:
-1.86%
1年 パフォーマンス:
+17.19%
1日の値動き範囲:
$144.46
$146.18
1週間の範囲:
$142.03
$147.03
52週間の値動き範囲:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
145.44 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,185.00 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.72 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.44 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.87 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Argus | Hold → Buy |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile - ChartMill
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Novartis stock gains 0.62 percent at the close - AD HOC NEWS
Novartis stock ends the day at USD 141.43 after the close - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis stock holds steady as investors weigh recent results and pipeline outlook - AD HOC NEWS
Novartis AGADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Novartis stock recovers after trial setbacks as analysts lift earnings outlook - AD HOC NEWS
Novartis stock stabilizes after trial setbacks as investor pushes for board shake-up - ad-hoc-news.de
Sarepta Therapeutics Inc Share PriceSRPT, RNS News, Articles, Quotes, & Charts (NASDAQ:SRPT) - Proactive financial news
NVS Stock Quote Price and Forecast - CNN
Why Did Novartis (NYSE:NVS) Shares React to Study Results? - Kalkine Media
US markets today: Dow, S&P 500, Nasdaq futures indicate negative open, PPI data in focus; Apple, Novartis, others to watch - Upstox
HSBC upgrades Novartis stock rating to hold on pipeline clarity - Investing.com
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Dow closes sharply lower as oil surge fuels inflation fears - Proactive financial news
Dow slides as oil nears $100, US-Canada trade tensions escalate - Proactive financial news
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - benzinga.com
Novartis stock falls sharply after third late-stage trial failure in a week - ad-hoc-news.de
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - finance.yahoo.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com.au
Novartis Down Over 12%, On Pace for Record Percent Decrease -- Data Talk - Moomoo
Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch - Upstox
Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease - Investing.com Nigeria
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis shares fall after second major trial setback in days - The Globe and Mail
Novartis shares plunge 10% as failed drug trial clouds growth outlook - Investing.com Nigeria
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - ad-hoc-news.de
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - ad-hoc-news.de
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - ts2.tech
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com Australia
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - ad-hoc-news.de
Novartis stock trades below consensus target as post-earnings digestion continues - AD HOC NEWS
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - AD HOC NEWS
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
0.76%
大文字化:
|
ボリューム (24 時間):